FDA Briefing Documents Question Safety, Efficacy of Sarepta’s DMD Gene Therapy

Sarepta’s biomarker-based data “do not provide unambiguous evidence” of the therapy’s likely benefit for Duchenne muscular dystrophy patients, according to the regulatory agency.